DCF — HONORHEALTH JOHN C. LINCOLN MED CTR
Enterprise Value: $-796.8M
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$-796.8M
Enterprise Value
$-256.7M
PV of Cash Flows
$-540.1M
PV of Terminal Value
$-869.8M
Terminal Value
10.0%
WACC
2.5%
Terminal Growth
Cash Flow Projections
PROJ| Year | Revenue | EBITDA | Margin | FCF | PV(FCF) |
|---|---|---|---|---|---|
| Year 1 | $637.0M | $-47.1M | -7.0% | $-74.1M | $-67.3M |
| Year 2 | $656.1M | $-42.0M | -6.0% | $-69.7M | $-57.6M |
| Year 3 | $675.7M | $-36.5M | -5.0% | $-65.1M | $-48.9M |
| Year 4 | $696.0M | $-34.1M | -5.0% | $-63.5M | $-43.4M |
| Year 5 | $716.9M | $-33.3M | -5.0% | $-63.6M | $-39.5M |
Interpretation
INTAt a WACC of 10.0% and terminal growth of 2.5%, enterprise value is $-796.8M. Terminal value accounts for 0% of total EV — consider sensitivity to terminal assumptions.
Next steps: Check the LBO model to see equity returns at this entry price, or the EBITDA bridge to model value creation levers.
Assumptions
ASSMrevenue base$618.4M
revenue growth rates[0.03, 0.03, 0.03, 0.03, 0.03]
ebitda margin base-0.07894184173180205
ebitda margin improvement bps[50, 100, 100, 50, 25]
capex pct revenue0.04
nwc pct revenue0.08
tax rate0.25
projection years5